Product Information
LANSOPRAZOLE DR 30 MG ODT is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $2.2558 per EA under NDC 68382077277. Its NADAC has been published 401 times since Jan 30, 2019.
FDA first approved this application on Nov 27, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the LANSOPRAZOLE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382077277
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LANSOPRAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA200816FDA Approved
11/27/2018
TE Code
AB
On Market Since
11/30/2018
Pharmacological Classes
Price Statistics
The NADAC for LANSOPRAZOLE DR 30 MG ODT has been published 401 times since Jan 30, 2019, and over the history we have for it it has declined 79.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.2558 per EA |
|---|---|
| All-time high | $11.2227 (Jun 12, 2019) |
| All-time low | $1.8384 (Apr 22, 2026) |
| 52-week high | $2.5180 |
| 52-week low | $1.8384 |
| Median price | $4.3560 |
| Average price | $5.0258 |
| Largest weekly change | +43.5% (Sep 22, 2021) |
| Weeks tracked | 401 |
| Tracking since | Jan 30, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LANSOPRAZOLE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
LANSOPRAZOLE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Proton Pump Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LANSOPRAZOLE DR 30 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for LANSOPRAZOLE DR 30 MG ODT, manufactured by Zydus Pharmaceuticals (USA) Inc., is $2.2558 per EA (NDC 68382077277), effective Sep 30, 2026.
How has the price of LANSOPRAZOLE DR 30 MG ODT changed over time?
Over the history we have for it, the NADAC for LANSOPRAZOLE DR 30 MG ODT has declined 79.9%. It has been tracked across 401 weekly CMS publications since Jan 30, 2019.
What are the highest and lowest recorded NADAC prices for LANSOPRAZOLE DR 30 MG ODT?
Since Jan 30, 2019, the NADAC for LANSOPRAZOLE DR 30 MG ODT has ranged from a low of $1.8384 (Apr 22, 2026) to a high of $11.2227 (Jun 12, 2019), with a median of $4.3560 per EA.
Are there cheaper alternatives to LANSOPRAZOLE DR 30 MG ODT?
No other NADAC-published product currently shares the active ingredient and strength of LANSOPRAZOLE DR 30 MG ODT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LANSOPRAZOLE DR 30 MG ODT?
LANSOPRAZOLE DR 30 MG ODT (NDC 68382077277) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.